Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case-control study using the All of Us database, no significant association was observed between alopecia areata and venous thromboembolism after controlling for hypercoagulable risk factors.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study found that patients with vitiligo in the United States had higher rates of autoimmune conditions, infections, and skin cancer compared to matched controls, with higher vitiligo prevalence in Asian and Hispanic populations.

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.

This scoping review aims to explore the impact of hormone therapy on the laboratory profiles of transgender people, identify evidence, and highlight literature gaps, particularly in developing countries.

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

This narrative review discusses the initiation and monitoring of gender-affirming hormone therapy in Australia, noting standard testosterone use for trans men and estradiol with anti-androgens for trans women, emphasizing the importance of monitoring cardiovascular and bone health.

This review discusses the long-term effects of gender affirming hormone therapy and reports no new clinical findings, recommending a shared decision-making approach to balance benefits and risks for transgender individuals.

This review updates dermatologists on both FDA-approved and off-label hormonal therapies, including combined oral contraceptives, clascoterone, and spironolactone, used for acne treatment, providing insights into emerging approaches for managing the condition.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This study reports that discrepancies in adverse event reporting for clinical blood pressure trials undermine the reliability of safety data, suggesting a need for standardized reporting guidelines to improve trustworthiness.

This abstract describes a program with various presentations and events focused on Canadian excellence in rheumatology but reports no new research findings.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

This article reviews the role of factor Xa inhibitors like Rivaroxaban and suggests they may eventually replace vitamin K antagonists, but their side effects require further clarification.

This study reviewed how Anifrolumab, though often used in real-world settings for SLE patients with neurological symptoms, showed varying effectiveness and required cautious monitoring for adverse effects like thrombocytopenia and cerebrovascular events.

Results are not reported for this abstract, which mentions that patients on antithrombotic therapy, important for preventing cardiovascular events, sometimes seek hair transplantation at the clinic.

This article reviews the importance of managing perioperative antithrombotic therapy to prevent cardiovascular events in patients with coronary heart disease or atrial fibrillation during surgery and reports no new findings.

This study found that individuals with hospital-treated alopecia areata in Denmark had increased standardized incidence rates of serious infections, herpes zoster infections, lymphoma, cardiovascular events, and death compared to the age- and sex-matched general population.

This study reviewed clinical trials on JAK inhibitors for alopecia areata, finding them effective for short-term hair regrowth with a favorable safety profile, but noted limited data on long-term risks like malignancies or cardiovascular events beyond two years.

This review discusses how various reproductive factors are linked to increased risks of hypertension and cardiovascular disease, noting associations with impaired fetal growth, male hypogonadism, and effects of contraceptive use, but reports no new results.

In this study, an ultra-low dose combination of estradiol and dydrogesterone significantly reduced hot flushes and improved health-related quality of life among a multi-ethnic population of postmenopausal women, with no notable difference in serious adverse events compared to placebo.

This case report describes a 23-year-old woman with alopecia areata who developed new central nervous system demyelination after starting tofacitinib therapy; while the drug was associated with this neurological event, causality is not confirmed. The demyelination was reversible upon stopping the medication and administering corticosteroids.

This case report describes Rumpel-Leede phenomenon in a patient without underlying conditions, occurring after pneumatic compression for venous thromboembolism prophylaxis, with spontaneous resolution upon stopping compression.

This case study identified non-criteria antiphospholipid syndrome as a potential underlying cause of Budd-Chiari syndrome in a patient, emphasizing the need for its consideration, especially in cases with multiple thromboemboli and thrombocytopenia.

This chapter reviews drugs affecting blood coagulation and details the increased hemorrhage risk associated with warfarin interactions, liver disease, heart failure, and antiphospholipid antibodies but reports no new clinical results.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

This review discusses the current understanding of polycystic ovary syndrome, focusing on its epidemiology, pathophysiology, diagnosis, management, and future research directions, but reports no new clinical results.

This study found that using autologous adipose-derived stromal vascular fraction enriched with platelet-rich plasma may improve healing rates in patients undergoing flap repair for transsphincteric cryptoglandular fistulas.

This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.